Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees and Multiple Sites
GLPG sits 55% above its 52-week low of $22.36.
Summary
Galapagos NV announced its Board of Directors has decided to initiate the wind-down of its cell therapy activities, following a strategic review and completion of works council consultations. This decision will impact approximately 365 employees and result in the closure of several sites.
Key Events · Corporate Governance and Compliance · GLPG
-
Strategic Wind-Down Initiated
Galapagos' Board of Directors has decided to initiate the wind-down of its cell therapy activities after completing works council consultations.
-
Significant Operational Impact
The wind-down will affect approximately 365 employees and lead to the closure of sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai.
-
Repositioning for Future Growth
The company will reposition for long-term growth through transformational business development, maintaining non-cell therapy activities like the GLPG3667 program.
-
Strong Cash Position
As of December 31, 2025, Galapagos held approximately €3.0 billion in cash and cash equivalents.
Analysis · GLPG · Life Sciences
This decision marks a significant strategic pivot for Galapagos, indicating a failure to achieve desired outcomes in its cell therapy division. While the immediate impact is negative due to job losses and site closures, the company aims to reposition for long-term growth through new business development and focus on its non-cell therapy pipeline, such as the TYK2 program GLPG3667. Investors should monitor the upcoming financial guidance for estimated wind-down costs and the company's progress in identifying new transformational opportunities.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLPG was trading at $34.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.36 to $37.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.